Dr. Dave Dixon and CardioScripts co-host, Dr. Liz Sulaica, discuss the EVAPORATE trial and where icosapent ethyl fits.
0:00-0:27: Intro
0:28-1:09: Introduction of Dr. Dave Dixon
1:10-4:38: EVAPORATE Overview
4:39-6:12: Overall thoughts about EVAPORATE
6:13-9:23: Trial limitations
9:24-11:55: Isocapent ethyl in practice – involve the patient in decision-making!
11:56-14:31: How has practice changed since REDUCE-IT?
14:32-15:31: Final thoughts
15:32-16:09: Closing
References
- Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J 2020; doi: 10.1093/eurheartj/ehaa652.
- Bhatt DL, Steg PG, Miller M , et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380:11-22.
- Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cadiovasc Res 2020; doi: 10.1093/cvr/cvaa184.
CardioScripts 